Christine Chin
Research Subjects
Christine Chin has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Adam J. Hockenberry
Tempus AI, Inc., Chicago, Illinois
23 shared publications - Ben Ho Park
Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN
23 shared publications - Bradley Bowles
Tempus AI, Inc., Chicago, Illinois
23 shared publications - Brittany Mineo
Tempus AI, Inc., Chicago, Illinois
23 shared publications - Halla Nimeiri
Tempus AI, Inc., Chicago, Illinois
23 shared publications - Justin Guinney
Sage Bionetworks, Seattle, USA
23 shared publications
Latest Publications
- Open Access
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 1 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 1 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- Open Access
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Fusion detection stratified by cancer indications with and without FDA-approved targeted therapy. A, Fusions detected in FDA-approved and non–FDA-approved indications aggregated across fusion drivers (see Supplementary Table S1). B, Percent of driver fusions detected by analyte for FDA-approved and non–FDA-approved indications. C, Counts of fusions detected in FDA-approved and non–FDA-approved indications by fusion driver.
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Fusion detection stratified by cancer indications with and without FDA-approved targeted therapy. A, Fusions detected in FDA-approved and non–FDA-approved indications aggregated across fusion drivers (see Supplementary Table S1). B, Percent of driver fusions detected by analyte for FDA-approved and non–FDA-approved indications. C, Counts of fusions detected in FDA-approved and non–FDA-approved indications by fusion driver.
- Open Access
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Gene expression and RNA fusion partners in FGFR2, FGFR3, and NRG1 fusions. A–C, Gene expression TPM by cancer type in fusion-positive and fusion-negative patients for (A) NRG1, (B) FGFR3, and (C) FGFR2. All FDA-approved indications and non–FDA-approved indications are separated by the gray lines. D–F, Fusion driver partners identified by RNA stratified by cancer type for the following fusions: (D) NRG1, (E) FGFR3, and (F) FGFR2. All FDA-approved indications and the top three non–FDA-approved indications by fusion count are shown, with the remaining non–FDA-approved indications grouped into the “other” cancer type category. Fusion partners that only appear in a single patient (or only in two patients in the case of FGFR2) are grouped into the “other” partner category. HNSCC, head and neck squamous cell carcinoma.
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Gene expression and RNA fusion partners in FGFR2, FGFR3, and NRG1 fusions. A–C, Gene expression TPM by cancer type in fusion-positive and fusion-negative patients for (A) NRG1, (B) FGFR3, and (C) FGFR2. All FDA-approved indications and non–FDA-approved indications are separated by the gray lines. D–F, Fusion driver partners identified by RNA stratified by cancer type for the following fusions: (D) NRG1, (E) FGFR3, and (F) FGFR2. All FDA-approved indications and the top three non–FDA-approved indications by fusion count are shown, with the remaining non–FDA-approved indications grouped into the “other” cancer type category. Fusion partners that only appear in a single patient (or only in two patients in the case of FGFR2) are grouped into the “other” partner category. HNSCC, head and neck squamous cell carcinoma.
- Open Access
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 13 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 13 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 13 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 13 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- Open Access
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 7 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 7 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- Open Access
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 5 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 5 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- Open Access
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 4 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 4 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- Open Access
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 10 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 10 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- Open Access
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 11 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 11 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
- 6 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 11 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors
Supplementary Table 11 from Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid Tumors